Poster presentation - American Association of Cancer Research 2002
Jack Henkin, Fortuna Haviv, Yi-Chun Wang, David Frost, Abdullah Kherzai, Frank K. Reiber, Olga V. Volpert, Susan E. Crawford, Noel P. Bouck, Steven C. Campbell, Chand Khanna

C. Khanna, T, Rusk, F. Haviv, and J. Henkin
Thrombospondin-1 (TSP-1) is a natural antiangiogenic protein that enhances apoptosis in activated endothelial cells (EC). D-amino acid substituted peptides within the TSP-1(Mal II) sequence inhibit EC function. A related antiangiogenic nonapeptide (ABT526) was found to slow tumor growth in syngeneic and xenograft mouse models. To examine the safety and efficacy of ABT526 antiangiogenic therapy a prospective pre-clinical trial in pet dogs with naturally occurring cancers was undertaken. Eligible cases had histologically confirmed measurable cancers, no cancer therapy within 21 days and no …

Anthony Rusk1, Elizabeth Cozzi2, Rick Sharpee2, David Vail3, Joanne Graham4, Barbara Kitchell, Chand Khanna1. Animal Cancer Institute LLC1, Columbia, MD, Abbott Laboratories, Inc2, N. Chicago, IL University of Wisconsin School of Veterinary Medicine3, Madison, WI Arboretum View Animal Hospital4, Downers Grove, IL, University of Illinois School of Veterinary Medicine5.
Thrombospondin-1 (TSP-1), a natural angiogenesis inhibitor, has been found to act broadly against a wide variety of proangiogenic growth factors. Its large molecular size and multifunctional nature has precluded its use as a therapeutic agent. Modified peptide segments of the antiangiogenic domain …